

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/705 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, WPI Data, MEDLINE

Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JAQUEMAR DANIEL ET AL: "An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 11, 12 March 1999 (1999-03-12), pages 7325-7333, XP002279015 ISSN: 0021-9258 page 7332, left-hand column, paragraph 2 -right-hand column, last paragraph; figures 1-3	1-23
X	WO 01/75067 A (HYSEQ INC ;LIU CHENGHUA (US); TANG Y TOM (US); DRMANAC RODOJE T (U) 11 October 2001 (2001-10-11) Sequence according to Seq. ID No. 47375. claims 1,10-12,17,28	1-23

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the International filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the International filing date but later than the priority date claimed	"T" later document published after the International filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
5 May 2004	02/06/2004
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fac (+31-70) 340-3016	Griesinger, I

BEST AVAILABLE COPY



Internal Application No PCT/EP 03/14403

		PCT/EP 03	3/14403
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
ategory °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
х	WO 01/18020 A (UNIV CALIFORNIA) 15 March 2001 (2001-03-15) Sequence according to Seq. ID No. 4 claim 18		11-14, 18-20
A	PEIER ANDREA M ET AL: "A TRP channel that senses cold stimuli and menthol" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 108, no. 5, 8 March 2002 (2002-03-08), pages 705-715, XP002246274 ISSN: 0092-8674 cited in the application page 711, left-hand column, paragraph 2-page 713, left-hand column, paragraph 1		1-23
A	MONTELL CRAIG ET AL: "The TRP channels, a remarkably functional family" CELL, vol. 108, no. 5, 8 March 2002 (2002-03-08), pages 595-598, XP002279016 ISSN: 0092-8674		
P,X	STORY GINA M ET AL: "ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures." CELL. UNITED STATES 21 MAR 2003, vol. 112, no. 6, 21 March 2003 (2003-03-21), pages 819-829, XP002279017 ISSN: 0092-8674 abstract		1-23





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 5-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: 11-14,17-20, and 22 (all claims partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
3	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	mational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	,
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.



Continuation of Box I.2

Claims Nos.: 11-14,17-20, and 22 (all claims partially)

Present claims 11-14,17-20, and 22 relate to a compound defined by reference to a desirable characteristic or property, namely the ability to modulate the nociceptive response of the protein according to the present application. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compound. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibodies (see claim 23).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



Into the Application No PCT/EP 03/14403

		PCI/EP 03/14403			
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0175067	Α	11-10-2001	AU	3486501 A	14-08-2001
			ΑU	3995501 A	12-09-2001
			ΑU	4925101 A	15-10-2001
			ΑU	4972801 A	15-10-2001
			ΑU	5119401 A	15-10-2001
			ΑU	5521401 A	15-10-2001
			CA	2399681 A1	09-08-2001
			CA	2404501 A1	11-10-2001
			CA	2404555 A1	11-10-2001
			ΕP	1254266 A1	06-11-2002
			ĒΡ	1268762 A1	02-01-2003
			EP	1268510 A2	02-01-2003
			JΡ	2004502403 T	29-01-2004
			JP	2004500120 T	08-01-2004
			WO	0157266 A1	09-08-2001
			WO	0164839 A2	07-09-2001
			WO	0175067 A2	11-10-2001
		•	WO	0175064 A2	11-10-2001
			WO	0174836 A1	11-10-2001
			WO	0175093 A1	11-10-2001
			US	2004048249 A1	11-03-2004
			US	2003092112 A1	15-05-2003
			US	2003087370 A1	08-05-2003
			US	2003096279 A1	22-05-2003
			US	6436703 BT	20-08-2002
			US	2002061567 A1	23-05-2002
			บร	2003180722 A1	25-09-2003
			US	2002146757 A1	10-10-2002
WO 0118020	Α	15-03-2001	US.	6537778 B1	25-03-2003
			ΑU	6510100 A	10-04-2001
			WO	0118020 A1	15-03-2001
			US	2003152991 A1	14-08-2003